A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

WW International shares plummeted Wednesday after the company, better known as WeightWatchers, filed for Chapter 11 ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

The 62-year-old company, which has moved into the prescription drug weight loss business, hopes to emerge from bankruptcy ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...